<DOC>
	<DOCNO>NCT01634412</DOCNO>
	<brief_summary>Very low dose ( VLD ) cyclobenzaprine bedtime show promise treatment fibromyalgia , chemistry cyclobenzaprine require new formulation technology bedtime use . The present trial design assess safety tolerability sublingual TNX-102 2.4 mg ( new formulation cyclobenzaprine design result increase dosage precision decrease potential morning grogginess ) pH 3.5 7.1 compare bio-availability sublingual TNX-102 2.4 mg pH 3.5 7.1 cyclobenzaprine ( 5 mg tablet , 2.4 mg iv ) .</brief_summary>
	<brief_title>Comparative Bioavailability Sublingual TNX-102 , Oral Intravenous Cyclobenzaprine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<criteria>Healthy adult Male female Nonsmoker 1865 year old BMI &gt; 18.5 &lt; 30.0 With medically acceptable form contraception ( female ) With sign informed consent Any clinically significant abnormality include ECG abnormality vital sign abnormality ( systolic blood pressure &lt; 90 &gt; 140 mmHg , diastolic blood pressure low &lt; 50 &gt; 90 mmHg , heart rate &lt; 50 &gt; 100 BPM ) Any abnormal laboratory test ( include positivity Hep B , Hep C , HIV , Hemoglobin &lt; 128 g/L ( male ) &lt; 115 g/L ( female ) hematocrit &lt; 0.37 L/L ( male ) &lt; 0.32 L/L ( female ) ) History alcohol drug abuse dependence within 1 year and/or positive drug , cotinine , alcohol test Use drug ( within 30 day ) , supplement , food ( within 14 day ) know induce inhibit hepatic drug metabolism prior study medication Positive pregnancy test , breastfeed lactate Use medication hormonal contraceptive topical product , include OTC , natural health product , MAO inhibitor Participation investigational study within 30 day prior dose Donation plasma ( within 7 day ) , donation loss blood 50499 mL ( within30 day ) , &gt; 499 mL ( within 56 day ) prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>